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Abstract
Recombinant herpesvirus vaccine vectors offer distinct advantages in next-generation vac-
cine development, primarily due to the ability to establish persistent infections to provide
sustainable antigen responses in the host. Recombinant bovine herpesvirus-4 (BoHV-4)
has been previously shown to elicit protective immunity in model laboratory animal species
against a variety of pathogens. For the first time, we describe the induction of antigen-spe-
cific immune responses to two delivered antigens in the host species after intranasal nebuli-
zation of recombinant BoHV-4 expressing the chimeric peptide containing the bovine viral
diarrhea virus (BVDV) glycoprotein E2 and the bovine herpesvirus 1 (BoHV-1) glycoprotein
D (BoHV-4-A-CMV-IgK-gE2gD-TM). In this study, four cattle were immunized via intranasal
nebulization with the recombinant BoHV-4 construct. Two of the cattle were previously
infected with wild-type BoHV-4, and both developed detectable serologic responses to
BVDV and BoHV-1. All four immunized cattle developed detectable viral neutralizing anti-
body responses to BVDV, and one steer developed a transient viral neutralizing response to
BoHV-1. Approximately one year after immunization, immunosuppressive doses of the glu-
cocorticoid dexamethasone were administered intravenously to all four cattle. Within two
weeks of immunosuppression, all animals developed viral neutralizing antibody responses
to BoHV-1, and all animals maintained BVDV viral neutralizing capacity. Overall, nebuliza-
tion of BoHV-4-A-CMV-IgK-gE2gD-TM persistently infects cattle, is capable of eliciting anti-
gen-specific immunity following immunization, including in the presence of pre-existing
BoHV-4 immunity, and recrudescence of the virus boosts the immune response to BoHV-4-
vectored antigens. These results indicate that BoHV-4 is a viable and attractive vaccine
delivery platform for use in cattle.
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Introduction
Bovine herpesvirus-4 (BoHV-4) is within the rhadinovirus genus in the gammaherpesvirus
subfamily of the Herpesviridae family [1]. As is typical of other gammaherpesviruses, BoHV-4
initially infects mucosal epithelial cells, and replicates and undergoes latency in monocytes
and macrophages [2]. BoHV-4 has been isolated from a variety of tissues from healthy cattle
[3, 4]. Although BoHV-4 has also been identified in diseased respiratory, enteric, and most
often, reproductive tissues, causal associations with disease have not been definitively estab-
lished, and experimental infection of cattle does not reliably result in overt clinical disease
[5, 6].
Herpesviruses have intrinsic properties that make them attractive for use as viral vaccine
vector candidates. Herpesviruses are capable of incorporating large amounts of foreign
genetic material and can undergo replication-competent persistent infections in the host. For
example, herpesvirus of turkeys (HVT) has been developed as successful, single dose veteri-
nary vaccine capable of producing long term protective responses against avian influenza in
chickens based in part on the ability to undergo persistent infection, even in the presence of
neutralizing maternal antibodies [7–10]. Thus herpesvirus vectors are thought to be capable
of priming and maintaining lifelong antigen-specific protective immunity. In addition to
these intrinsic biological properties of herpesviruses, BoHV-4 is non-oncogenic and avirulent
under experimental challenge conditions [6]. In light of these properties, BoHV-4 has been
successfully developed as a veterinary vaccine vector in model animal species against a variety
of infectious diseases. BoHV-4-vectored vaccines have successfully induced neutralizing anti-
body responses to bovine herpesvirus-1 (BoHV-1) and Bovine Viral Diarrhea Virus (BVDV)
type 1 in rabbits [11, 12], neutralizing antibody responses to BVDV type 1 in sheep [13], neu-
tralizing antibody responses to Bluetongue virus and to Peste de Petits Ruminants (PPR)
virus in mice, respectively [14, 15], and protective viral neutralizing antibody responses
against caprine herpesvirus-1 in goats [16]. Despite the success of the BoHV-4 platform in
these non-BoHV-4 host species, and the intrinsic benefits of the BoHV-4 platform, immuni-
zation using BoHV-4 has never been attempted in cattle. The seroprevalence of BoHV-4 in
cattle populations varies widely in different geographical regions; recently, typical global
seroprevalence estimates vary between 4–30% [17]. Some dairy herds experience up to 88%
seroprevalence [18] and wild African buffalo populations reportedly have up to 94% sero-
prevalence [19]. Given the seroprevalence of BoHV-4 in most bovid populations, it is critical
to determine whether pre-existing immunity directed at the vector could preclude the devel-
opment of antibody responses to the vaccine antigen after BoHV-4-vectored immunization.
This is a concern with other viral vaccine delivery systems, particularly with the use of adeno-
viral vectors [20]. Specifically, reduction in recombinant adenoviral vaccine vector efficiency
attributed to decreased transgene transduction has been described following vaccination of
humans that had pre-existing neutralizing antibodies developed to circulating strains of ade-
novirus [21].
The immunodominant BVDV type 1-derived antigen E2 and BoHV-1-derived glycopro-
tein D were used as the model immunogens, and were expressed as a chimeric protein by
recombinant BoHV-4 (BoHV-4-A-CMV-IgK-gE2gD-TM). This recombinant BoHV-4 con-
struct expressing E2 and gD has been used to effectively produce antigen-specific immunity in
previous studies using a rabbit model [12, 22]. Additionally, E2 and gD antigens have been
experimentally shown to incite protective immune responses in cattle to BVDV and BoHV-1,
respectively [23, 24]. The VN immune response reported in these experimental subunit vac-
cines meets the standardized requirements for commercial vaccines that protect against
BVDV and BoHV-1 associated disease according to the United States Department of
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Agriculture Animal Plant Health inspection services Code of Federal Regulations (9 CFR §
113.215 and 113.216, respectively) [25]. The development of VN antibody titers correlates with
clinical immune protection from disease, and thereby abrogates the requirement to challenge
immunized cattle with virulent virus to verify protection [26]. The use of model antigens that
obviate challenge studies are desirable to meet Assessment and Accreditation of Laboratory
Animal Care (AALAC) and Animal Welfare Act goals of replacement, reduction, and refine-
ment of animal use in research.
The aims of this study were three-fold: to assess whether immunization of cattle with
recombinant BoHV-4 expressing model antigens could elicit antigen-specific protective
immune responses, to determine whether recombinant BoHV-4 can persistently infect cattle,
and to determine whether pre-existing immunity to BoHV-4 precludes its use as a vaccine vec-
tor in cattle. The results of this study provide evidence of the utility of recombinant BoHV-4 as




The wild-type and recombinant BoHV-4 viruses used in this study were constructed as
previously described [22]. Briefly, the BoHV-4 genome was originally cloned as a bacterial
artificial chromosome, and the BAC cassette was inserted into the BoHV-4 genome by
homologous recombination (pBAC-BoHV-4-A). The thymidine kinase (TK) region was tar-
geted by insertion of a galactokinase prokaryotic expression cassette (GalK) and kanamycin
resistance expression cassette (KanaGalK) flanked by the TK region via electroporation and
subsequent double positive selection (pTK-KanaGalK-TK). The pCMV-IgK-gE2gD-TM
plasmid flanked by the TK region retargeted the selection cassette during heat-inducible
homologous recombination to produce pBAC-BoHV-4-A-CMV-IgK-gE2gD-TM. Trans-
fected cell membrane-associated protein expression was detected by both anti-gD and gE2
monoclonal antibodies by Western immunoblotting as previously described [22]. Electropo-
ration into BEKcre cells expressing cre recombinase eliminates the BAC cassette from the
viral genome. Infectious BoHV-4-A-CMV-IgK-gE2gD-TM virus is obtained by freezing and
thawing BEKcre cells three times and pelleting virions through 30% sucrose. WT BoHV-4 is
generated similarly by electroporating pBAC-BoHV-4-A into BEKcre cells expressing cre
recombinase, undergoing three freeze/thaw cycles, and pelleting the virions. Viruses were
propagated by infecting confluent monolayers of Madin Darby Bovine Kidney (MDBK) cells
at an MOI of 0.5 TCID50 per cell and maintaining them in minimal essential medium
(MEM) with 10% fetal bovine serum (FBS) for two hours. The medium was then removed
and replaced with fresh MEM containing 10% FBS. When approximately 90% of the cell
monolayer exhibited cytopathic effect (CPE), approximately 72 hours postinfection, the virus
was prepared by freezing and thawing cells three times and pelleting virions through 30%
sucrose. Virus pellets were resuspended in cold MEM without FBS. TCID50 were determined
on MDBK.
MDBK cells were infected at an MOI of 0.5 PFU/cell and incubated at 37˚C for four hours.
Infected cells were washed with serum-free Eagle’s MEM and then overlaid with Eagle’s MEM
containing 10% FBS, 2 mM of l-glutamine, 100 IU/ml of penicillin (Sigma-Aldrich, St. Louis,
Missouri, USA), 100 μg/ml of streptomycin (Sigma-Aldrich) and 2.5 μg/ml of amphotericin B.
The supernatants of infected cultures were harvested every 24 h, and the amount of infectious
virus was determined.
Bovine herpesvirus-4 as a novel vaccine vector in cattle
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Cattle
Four, six-month-old Holstein-cross steers were acquired from a dairy in central Washington
and maintained in accordance with the Washington State University and University of Idaho
Institutional Animal Care and Use Committees, approved protocol numbers 04596 (WSU),
04975 (WSU) and 2016–18 (U of I). The four cattle were housed together at approved WSU
and USDA-ARS research barns in Moscow, ID and Pullman, WA for the duration of this
study. Cattle were quarantined for two weeks following acquisition, and were serologically
tested for the presence of pre-existing antibodies to BoHV-1, BoHV-4, and BVDV during this
time.
Infection of cattle with WT BoHV-4
Two of the steers (steers 1 and 2) were infected with 2.0 mL of a 107 TCID50 /mL preparation
of WT BoHV-4 via nebulization, as previously described [27]. Briefly, cattle were restrained in
a head catch with a large cloth draped over both eyes. Intranasal immunization was achieved
by slight modification of a commercially available human nebulization system (Devilbiss Pul-
moAide nebulizer, Sunrise Medical, Somerset, PA). One end of a 20 cm long, 0.5 cm diameter,
PVC polymer clear plastic tube was fitted to the chamber of the nebulizer, and the other end
was inserted approximately 5 cm into the left nasal passage of each animal. Over a six minute
period, the 2 mL virus preparation was delivered via nebulization as the steers respired. A
physical examination, including assessment of rectal temperature, pulse, and respiration rate,
was performed daily for 14 days post-infection. Blood was collected via jugular venipuncture
every other day for three weeks and then weekly for the remainder of the study for use in sero-
logic, molecular, and viral-culture based assays.
Immunization of cattle
All steers were immunized with recombinant BoHV-4-A-CMV-IgK-gE2gD-TM. Steers 1
and 2, which were first infected with WT BoHV-4 were immunized with 2.0 mL of a 105
TCID50 /mL preparation of BoHV-4-A-CMV-IgK-gE2gD-TM via nebulization as described
above approximately six months after infection with WT BoHV-4. At this time, the remaining
two age-matched steers with undetectable BoHV-4 antibody titers (steers 3 and 4) were immu-
nized with an identical preparation of BoHV-4-A-CMV-IgK-gE2gD-TM. All cattle were
boosted with the same recombinant viral preparation via the intranasal nebulization route ten
weeks later. Blood collection and physical examinations were performed as described for WT
BoHV-4 infection.
Dexamethasone suppression
Dexamethasone suppression was performed as described previously [28]. Briefly, 0.1 mg/kg
dexamethasone was administered intravenously to each steer once daily for five days. For the
next 14 days, cattle were examined daily for evidence of recrudescent herpesviral infection,
including elevated rectal temperature, nasal or ocular discharge, mucosal lesions, cough, and
elevated heart or respiratory rate. Ten days prior to euthanasia, dexamethasone suppression
was repeated via administration of 0.1 mg/kg dexamethasone intravenously to each steer once
daily for three days. Blood was collected at regular intervals via jugular venipuncture following
dexamethasone suppression. Nasal swabs were collected every other day for two weeks follow-
ing dexamethasone administration. Nasal specimens were collected bilaterally from the nares
of each steer with a dry swab by inserting the tip of the collection swab approximately 5 cm
into the nares and rolled five times, and were transported in universal transport medium (BD
Bovine herpesvirus-4 as a novel vaccine vector in cattle
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Diagnostics, Sparks, MD, USA). Collected specimens were transported at room temperature
and stored at -20˚C.
Post-mortem analysis
Cattle were euthanized via intravenous injection of sodium pentobarbital (Fatal Plus; Vortech
Pharmaceuticals, USA) and a complete necropsy performed on all steers within two hours of
death. Fresh samples of the trigeminal nerve ganglia, brainstem, cerebral cortex, lung, liver,
kidney, spleen, tracheobronchial lymph node, and bone marrow were collected and frozen at
-20˚C for use in viral isolation.
BoHV-4 viral isolation
All BoHV-4 isolations were performed using MDBK cells in Dulbecco’s Modified Eagle’s
Medium (DMEM) media (Sigma-Aldrich) supplemented with 10% FBS (Sigma-Aldrich), 2
mM l-glutamine (Sigma-Aldrich), 100 IU/ml of penicillin (Sigma-Aldrich), and 100 μg/ml of
streptomycin (Sigma-Aldrich), referred to as complete DMEM (cDMEM). Co-cultures were
performed from the peripheral blood leukocyte fraction (PBL; buffy coat) of approximately 10
mL of whole blood collected into EDTA Vacutainer tubes (BD Diagnostics) from steers. Blood
was centrifuged at 1000 x g for 15 minutes, and the buffy coat transferred to a new 15 mL
conical plastic tube. The cells were washed three times in PBS, and resuspended in 1.0 mL
cDMEM. 200 uL of this preparation was inoculated into duplicate wells of a 24-well plate con-
taining 90% confluent MDBK cells and cultured at 37˚C supplemented with 5% CO2 in
cDMEM. Cells were visualized daily using an inverted microscope for the appearance of CPE.
After five days, MDBKs that had not developed CPE were passaged using three, -80˚C freeze/
thaw cycles followed by centrifugation at 1300 x g for 5 minutes to remove cellular debris. The
supernatant was inoculated onto fresh MDBKs for observation. Cells that developed CPE were
prepared for DNA extraction and PCR analysis to confirm BoHV-4 infection. Viral isolation
from nasal swab media was performed similarly using transport media that has undergone
three -80˚C freeze/thaw cycles and subsequent inoculation of 200 uL of the transport media
onto 90% confluent MDBK cells as described above. For isolation from tissue samples, tissues
collected postmortem were minced into 0.1 to 0.5 cm3 segments and suspended in 0.25% tryp-
sin at 37˚C for five minutes. The samples were centrifuged at 150 g for 10 min, and the super-
natant mixed 1:1 in cDMEM and overlaid onto 90% confluent MDBK cells in 24-well tissue
culture plates at 37˚C and 5% CO2, as described above.
DNA extraction and BoHV-4 PCR
Genomic DNA was extracted (DNEasy Blood and Tissue Kit, Qiagen, Maryland, USA) and
eluted in a final volume of 100 μL. PCR was performed using Accuprime Pfx Supermix (Ther-
moFisher, Austin, Texas, USA) in a 27 μL reaction volume using 2 μL DNA template and 450
nM of each primer. The primer sequences were obtained from the inner portion of PCR
described previously for use in nested PCR [5, 29]: forward primer sequence (5’-TTGATAGT
GCGTTGTTGGGATGTGGT-3’) and reverse primer sequence (5’CACTGCCCGGTGGGAAAT
AGCA-3’). PCR cycling was 95˚C for 5 minutes followed by 35 cycles of 94˚C for 30 seconds,
55˚C for 10 seconds and 68˚C for 30 seconds followed by electrophoresis on a 1.25%, 1x TAE
agarose gel. Negative control samples included DNA extracted from uninfected MDBK cells
and positive control samples included DNA extracted from MDBKs infected in vitro with 1.0
Multiplicity of Infection (MOI) BoHV-4-A.
Bovine herpesvirus-4 as a novel vaccine vector in cattle
PLOS ONE | https://doi.org/10.1371/journal.pone.0215605 April 19, 2019 5 / 16
BoHV-4 serology
An indirect BoHV-4 ELISA (BIO-X, Brussels, Belgium) was performed per the manufacturer’s
instructions. Briefly, microtiter plates were coated in pairs with purified BoHV-4 and negative
control cell lysate provided by the manufacturer. Kit positive and negative serum samples and
test serum samples were diluted 1:100 and added to individual wells. After washing, each well
was incubated in horseradish peroxidase-labeled conjugate, washed, and incubated for ten
minutes in the provided chromogen substrate. The color reaction was stopped with phospho-
ric acid and the optical density (OD) value was determined by an ELISA plate reader at 450
nm. Percent positivity was calculated by dividing the difference in the OD of the cell lysate and
virus-coated wells for each sample by the difference in OD of the kit-provided positive sample
and multiplied by 100, as shown:
Value percent positivityð Þ ¼
Delta OD ðsample wellsÞ
Delta OD ðpositive control wellsÞ
x 100
The positive cut-off suggested by the manufacturer is 30% positivity. The cut-off for positiv-
ity routinely used in our lab is 14.5%. This is based on previous serologic evaluation of regional
field samples using 42 cattle, in which the average percent positivity was 7.73%, with a standard
deviation of 2.25. The cutoff for a positive was calculated as three times the standard deviation
plus the average percent positivity.
BoHV-1 serology
A commercial BoHV-1 indirect ELISA (IDEXX, Hoofddorp, The Netherlands) was performed
as described by the manufacturer instructions. Briefly, manufacturer-provided microtiter
plates coated in ultrapurified BoHV-1 infected cell lysate were incubated for one hour at 37˚C
with duplicate samples of the test serum, and the provided negative and positive control sera.
All sera samples were diluted 1:100 in dilution buffer and added to individual wells. After
washing three times with wash solution, each well was incubated for 30 minutes at 37˚C in
horseradish peroxidase-labeled conjugate, washed, and incubated for 20 minutes at room tem-
perature in the provided tetramethylbendizine (TMB) chromogen substrate. The color reac-
tion was stopped with sulfuric acid and the OD value was determined by an ELISA plate
reader at 450 nm. Percent positivity was calculated by dividing the difference in the OD of
each test sample and negative control by the difference in OD of the kit-provided positive and
negative sera samples and multiplied by 100, as shown:
Negative control value ¼
Delta OD ðnegative control wellsÞ
2
Positive control value ¼
Delta OD ðpositive control wellsÞ
2
Value percent positicityð Þ ¼
OD ðsampleÞ   Negative control value
Positive control value   Negative control value
The positive cut-off was interpreted in accordance with the manufacturer’s guidelines, with
any value above 50% considered positive.
Bovine herpesvirus-4 as a novel vaccine vector in cattle
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BVDV and BoHV-1 diagnostic assays
Following immunization, whole blood and serum from each steer were submitted weekly to
the Washington Animal Disease Diagnostic Laboratory (WADDL, Pullman, WA) for BVDV
and BoHV-1 diagnostic tests. Whole blood in EDTA was used for BVDV PCR and BoHV-1
PCR, and serum used for BVDV virus neutralization, BoHV-1 virus neutralization, and
BVDV Erns antigen ELISA testing. WADDL is fully accredited by the American Association of
Veterinary Laboratory Diagnosticians (AAVLD) and is a member of the National Animal
Health Laboratory Network, and all testing procedures have been validated through these
channels.
In brief, for the virus neutralization (VN) assays, each test serum sample and positive and
negative controls (NVSL) were initially diluted 1:4 using 50 μL of serum in 150 μL of cDMEM
in 96-well plates. Serial two-fold dilutions of each sample were then made in duplicate.
Twenty-five μL of virus suspension containing 100 TCID50 of BVDV or BoHV-1 (BVDV type
1 SINGER strain, BVDV type 2 125 genotype 2 strain, and BoHV-1 Colorado strain, respec-
tively) were added to respective wells. After one hour of incubation at 37˚C, 150 μl of a 104
cells/mL bovine turbinate cell suspension was added to each well and the plates were incubated
for three days at 37˚C in a humidified incubator supplied with 5% CO2. Cytopathic effect
(CPE) was detected using inverted light microscopy. Neutralizing antibody titers were
expressed as the reciprocal (log 2) of the final dilution of serum that completely inhibited viral
infectivity.
A commercially available BVDV type 1 and type 2 Erns antigen detection ELISA (IDEXX,
Westbrook, Maine, US) was performed per the manufacturer’s instructions. Briefly, manufac-
turer-provided microtiter plates coated in Erns-specific monoclonal antibody and 50 μL manu-
facturer-provided detector antibody were incubated for one hour at 37˚C with duplicate
samples of the test serum, and the provided negative and positive control sera. After washing
three times with wash solution, each well was incubated for 30 minutes at 37˚C in horseradish
peroxidase-labeled conjugate, washed, and incubated for 30 minutes at room temperature in
the provided TMB chromogen substrate. The color reaction was stopped with sulfuric acid
and the OD value was determined by an ELISA plate reader at 450 nm. Calculations were per-
formed by dividing the difference in the OD of each test sample and negative control by the
difference in OD of the kit-provided positive and negative sera samples, as shown:
Negative control value ¼
Delta OD ðnegative control wellsÞ
2
Positive control value ¼
Delta OD ðpositive control wellsÞ
2
Value ¼
OD ðsampleÞ   Negative control value
Positive control value   Negative control value
The positive cut-off was interpreted in accordance with the manufacturer’s guidelines, with
any value greater than or equal to 0.15 considered positive.
For BoHV-1 detection from the peripheral blood, a real time PCR (RT-PCR) was used.
Genomic DNA was extracted (DNEasy Blood and Tissue Kit; Qiagen) and eluted in a final vol-
ume of 100 μL. PCR was performed as previously described [30] using 10 μl Multiplex PCR
Master Mix (ThermoFisher), 2.0 μl dNTP mix (Bioline, Memphis, Tennessee, USA), 1.25 μl
forward primer, 1.25 μl reverse primer, 2.5 μl probe, and 3.0 μl water in a total reaction volume
of 20 uL. The primer sequences were used as follows: forward (5’-
Bovine herpesvirus-4 as a novel vaccine vector in cattle
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TGCCCTACAGGTCGTTGATTA-3’), reverse (5’-TCCAGCTGCCTCCTCTGTTT-3’), and
probe sequence 5’ FAM-CGTGTGCTTCTCGGCAGTCATCA-BHQ-1 3’. The PCR reactions
were performed at 95˚C for 15 minutes followed by 40 cycles of 94˚C for 60 seconds, 55˚C for
30 seconds and 72˚C for 30 seconds. Water was used as the negative control sample, and the
positive control DNA sample was extracted from BoHV-1 infected cells as described above in
the VN assay. The values were obtained from the generated curves where the x–axis represents
the PCR cycle number and the y-axis represents the relative fluorescence. Samples with detect-
able signals were reported as positive (data not shown).
For detection of BVDV types 1 and 2 from the peripheral blood, RT- PCR was performed.
RNA extractions were performed using MagMax-96 Viral RNA Isolation Kit (ThermoFisher),
and eluted in a final volume of 90 μL. Real time PCR was performed as previously described
[31] using the BVDV detection kit (Vet-MAX Gold, ThermoFisher, Austin, Texas, USA) con-
taining 12.5μl of RT-PCR buffer, 1.0 μl BVDV primer/probe, 0.2 μl XenoRNA-01, and 1.0 μl
RT-PCR enzyme mix in a total reaction volume of 14.7 μL. The primer sequences were used as
follows: forward sequence (5’-GTAGTCGTCAGTGGTTCG-3’), and a proprietary reverse
primer and probe. The PCR reactions were performed at 45˚C for 10 minutes, 95˚C for 10
minutes, followed by 40 cycles of 95˚C for 15 seconds, 60˚C for 45 seconds. Water was used as
the negative control sample, and the positive control DNA sample was extracted from BVDV
(BVDV Type I Singer strain, NVSL) infected cells as described above in the BVDV VN assay.
The control-based threshold (Ct) values were obtained from the generated curves, and samples
with Ct values below or equal to 38.0 were reported as positive (data not shown).
Results
Infection of cattle with WT BoHV-4 via intranasal nebulization
We tested whether cattle could be infected with BoHV-4 via the respiratory route using intra-
nasal nebulization. Seven days post-infection (PI), steers 1 and 2 developed a marked, transient
pyrexia of 40.6˚C and 40.9˚C, respectively. On all other days within the first two weeks PI, rec-
tal temperature measurements of both animals were below 39.2˚C. Neither steer developed
detectable adverse clinical signs or evidence of systemic disease, including respiratory, urogen-
ital, or gastrointestinal disease at any time during the two-week PI period. Infectious BoHV-4
was co-cultured from PBLs on day seven PI from steer 2 and on day 17 PI from steer 1, and
was verified by BoHV-4-specific PCR. BoHV-4 was not recoverable from PBLs on any other
date. Both calves developed anti-BoHV-4 serologic responses within approximately nine
weeks PI, and maintained detectable levels by indirect ELISA for the remainder of the study,
with the exception of one time point at week 44 (Fig 1, panel A). Because of the speculation
that BoHV-4 infection and resultant pre-existing immunity to the vector could preclude the
development of antibody responses to the vaccine antigen after BoHV-4-vectored immuniza-
tion, we next decided to immunize these two, BoHV-4-immune calves with recombinant
BoHV-4-A-CMV-IgK-gE2gD-TM. In this case, development of an antibody response to
BVDV and BoHV-1 following BoHV-4-A-CMV-IgK-gE2gD-TM immunization would indi-
cate that BoHV-4 is an effective vaccine vector, even in the face of pre-existing anti-BoHV-4
immunity.
Immunization of BoHV-4 immune-cattle with BoHV-4-A-CMV-IgK-
gE2gD-TM using intranasal nebulization
At the onset of this experiment, the two BoHV-4-immune steers had pre-existing viral neutral-
izing (VN) BVDV antibody titers, but were negative for BVDV by PCR and Erns antigen
Bovine herpesvirus-4 as a novel vaccine vector in cattle
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Fig 1. Antibody responses to antigens in each steer. Data trends were fit by Loess (degree = 2, smoothing = 0.3), and
original data are shown as symbols. The solid gray lines indicate positive cut-off values as suggested by the kit
manufacturer for each respective ELISA kit, and the dotted grey line indicates the positive cut-off value as calculated
for the geographical region. Steers 1 (blue) and 2 (red) (top) were WT-BoHV-4- infected (wt +) and steers 3 (green)
and 4 (brown) (bottom) were immunized only with BoHV-4-A-CMV-IgK-gE2gD-TM (wt -). WT-BoHV-4 infection
is indicated in the first 24 weeks, immunization with BoHV-4-A-CMV-IgK-gE2gD-TM occurred at week 24, and
dexamethasone-induced suppression took place during week 77. Panel A. BoHV-4 antibody percent positivity as
Bovine herpesvirus-4 as a novel vaccine vector in cattle
PLOS ONE | https://doi.org/10.1371/journal.pone.0215605 April 19, 2019 9 / 16
testing. Since BVDV is endemic in our region, these data indicate that titers were due to either
previous, resolved BVDV infection or lingering maternal antibody from colostrum acquired
shortly after birth. Despite this, we chose to include these cattle because successful vaccination
would elicit an increase in BVDV VN antibody titers due to an anamnestic response to E2 and
the development of anti-BoHV-1 antibody responses would indicate successful vaccination.
Indeed, within three weeks of the first BoHV-4-A-CMV-IgK-gE2gD-TM immunization,
BVDV VN titers increased logarithmically in both of these calves (Fig 1, panel B). In addition,
both steers developed detectable antibody titers to BoHV-1 on indirect ELISA (Fig 1, panel C),
but neither developed detectable VN responses to BoHV-1 post immunization (Fig 1, panel
D). Because detection of recrudescent BoHV-4 by viral isolation (VI) following dexametha-
sone suppression of cattle has been described [32], VI was attempted in these cattle after dexa-
methasone immunosuppression, and was unsuccessful in both steers. However, following
dexamethasone suppression 77 weeks after the onset of the experiment, both steers maintained
VN antibody responses to BVDV (Fig 1, panel B). The magnitude of BoHV-1 seropositivity
increased dramatically based on indirect ELISA (Fig 1, panel C), and both steers developed
and maintained VN titers to BoHV-1 within two weeks of dexamethasone administration that
remained for the duration of the study (Fig 1, panel C).
Immunization of BoHV-4-naïve cattle with BoHV-4-A-CMV-IgK-
gE2gD-TM using intranasal nebulization
This experiment additionally used two, age-matched BoHV-4 seronegative steer calves, steers
3 and 4, to further evaluate the vaccination serology kinetics. Within twelve weeks after the
first immunization, at week 36 after the onset of the experiment, both steers developed detect-
able BoHV-4 titers (Fig 1, panel A). Steer 4 remained seropositive until week 39. At that point,
anti-BoHV-4 antibody titers declined below the level of detection until the animals underwent
dexamethasone suppression during week 77, at which point, both steers regained and main-
tained BoHV-4 seropositivity until the end of the study (Fig 1, panel A). Both calves developed
BVDV VN titers within seven weeks after the first immunization, at week 31, and those VN
anti-BVDV titers were maintained for the remainder of the experiment (Fig 1, panel B).
At the onset of this experiment, steer 3 had pre-existing antibody titers to BoHV-1 based on
the indirect ELISA results (Fig 1, panel C). This positivity is attributed to residual maternal anti-
body due to the fact that BoHV-1 was not detected via PCR or VI from the peripheral blood or
nasal swab specimens at any time point, even following dexamethasone suppression, which reli-
ably causes detectable recrudescence of latent BoHV-1 in the peripheral blood and nasal secre-
tions [33–35]. BoHV-1 ELISA titers increased dramatically in both animals by two weeks after
immunization, at week 26 (Fig 1, panel C). Steer 3, which had preexisting BoHV-1 titers devel-
oped transient BoHV-1 VN titers detectable on weeks 28 and 31, which declined to undetectable
levels until after dexamethasone suppression. Both steers developed VN antibody responses to
BoHV-1 within two weeks of dexamethasone suppression (Fig 1, panel D). Viral isolation after
immunization and dexamethasone immunosuppression was unsuccessful in both steers.
Discussion
The results of this study indicate that nebulization of BoHV-4-A-CMV-IgK-gE2gD-TM is
capable of eliciting and maintaining BoHV-4-vectored antigen-specific immunity following
determined by indirect ELISA. Panel B. BVDV antibody response as determined by VN. Panel C. BoHV-1 antibody
response as determined by indirect ELISA. Panel D. BoHV-1 antibody response as determined by VN.
https://doi.org/10.1371/journal.pone.0215605.g001
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immunization, including in the presence of pre-existing BoHV-4 immunity. Thus, BoHV-4
is a viable and attractive vaccine delivery platform for use in cattle. Livestock production
demands have increased steadily for decades, and are projected to continue to trend upwards
on a global scale [36, 37]. As production demands increase, efficient methods of disease pre-
vention in bovine herd health management are necessary. The provision of long-term, or even
lifelong, immunity with a single dose of vaccine would be an obvious advantage for many
types of cattle operations, including large-scale production systems and small-holder agropas-
toralists. Additionally, the development of polyvalent recombinant vaccines to immunize
against multiple pathogens using a single vaccination would similarly increase the level of effi-
ciency for large-scale vaccination strategies. Given the ability of BoHV-4 to persistently infect
cattle and the ability to accommodate large amounts of foreign genetic material, as evidenced
by the inclusion of multiple antigens in this study, makes the development and use of BoHV-4
appealing as a vaccine vector for use in cattle.
The decision to pursue the intranasal/intrapulmonary route was based on natural gamma-
herpesvirus pathogenesis, which establishes infection in mucosal epithelial cells and subse-
quently undergoes persistent infection within monocytes and macrophages. Previous studies
have shown successful infection via nebulization of cattle with the gammaherpesvirus ovine
herpesvirus-2 [38]. However, prior studies using recombinant BoHV-4 as a vaccine vector uti-
lized subcutaneous [16] or intravenous (IV) [11, 12] administration. Specifically, immuniza-
tion of rabbits using a BoHV-4-A-CMV-IgK-gE2gD-TM construct was performed via IV
injection. Since the efficacy of BoHV-4 infection and immunization after intranasal/intrapul-
monary administration had not been previously verified, we used nebulization to infect two
calves with WT BoHV-4, and successfully established infection in both steers. Due to the tim-
ing of experimental infection and lack of any associated clinical evidence of disease, the tran-
sient fever detected in both steers on day seven likely reflects primary viremia associated with
acute BoHV-4 infection. Similar findings have been reported in other experimental BoHV-4
infections of cattle inoculated via the intramammary, intradermal, and IV methods [6]. Detec-
tion of virus in the blood of one of these steers on this day further corroborates this hypothesis,
and BoHV-4 was detected via PBL co-culture and verified by PCR in the other steer on day 17
PI. Although the dogma of herpesvirus infections dictates that all infections are persistent,
PCR-based diagnostic tests and direct viral culture of blood can be difficult, especially after
approximately three weeks post- experimental inoculation of BoHV-4 [5]. Consistent with
these results, we were unable to culture virus from PBLs in either steer after the second week
following infection with WT BoHV-4. Both steers developed a variably detectable anti-BoHV-
4 antibody response over the course of approximately one year post-immunization. Despite
successful WT BoHV-4 infection and subsequent anti-BoHV-4 immune response develop-
ment in these calves, both animals developed immune responses to recombinant vaccine anti-
gens after subsequent superinfection with BoHV-4-A-CMV-IgK-gE2gD-TM. Thus, previous
exposure to natural BoHV-4 infection and the presence of preexisting anti-BoHV-4 antibodies
should not be considered a deterrent or disadvantage to immunization with recombinant
BoHV-4, consistent with what has been described with other herpesvirus vectors [39, 40].
Although these two steers had pre-existing VN antibody titers to BVDV at the onset of the
study, they tested negative for the BVDV Erns antigen and were PCR negative for BVDV at all
time points throughout the study, thereby ruling out BVDV reinfection as the cause of the log-
arithmically increased anamnestic BVDV VN titer observed following BoHV-4-A-CMV-IgK-
gE2gD-TM immunization. That data, coupled with the development of anti-BoHV-1 antibody
titers following BoHV-4-A-CMV-IgK-gE2gD-TM immunization, supports the use of BoHV-4
as a vaccine vector, even in animals previously infected and with active immune responses to
BoHV-4.
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In contrast to the anti-BoHV-4 serologic response observed following WT BoHV-4 inocu-
lation, anti-BoHV-4 antibody levels were not sustained above cut-off levels in the two steers
immunized with the recombinant virus after 15 weeks post-immunization, on week 39 of the
study. This may have resulted from the lower immunization dose of recombinant BoHV-
4-A-CMV-IgK-gE2gD-TM compared to WT BoHV-4, or a decreased ability of recombinant
virus to establish infection or replicate in vivo. Previous data indicate that various BoHV-4
recombinants, including the BoHV-4-A-CMV-IgK-gE2gD-TM construct, maintain essentially
equal growth curves in vitro [12]. However, since the starting titer of the two purified virus ali-
quots differed, a direct comparison could not be established in this study. In vivo infection,
growth, and latency characteristics of WT BoHV-4 or recombinant BoHV-4-A-CMV-IgK-
gE2gD-TM have not been fully characterized in any species, including the natural host.
Despite the less robust anti-BoHV-4 antibody response observed following immunization
with BoHV-4-A-CMV-IgK-gE2gD-TM, both steers developed VN anti-BVDV and non-neu-
tralizing antibody titers to BoHV-1. Steer 3, immunized with only the recombinant BoHV-
4-A-CMV-IgK-gE2gD-TM construct, was seropositive for BoHV-1 at the onset of the study.
This is suspected to reflect maternal antibody interference since this animal never developed a
detectable BoHV-1 viremia and had no evidence of BoHV-1 infection based on PCR testing
and post-dexamethasone VI. Thus, the increase in anti-BoHV-4 antibody titers, coupled with
the transient detection of VN anti-BoHV-1 antibodies after immunization with BoHV-
4-A-CMV-IgK-gE2gD-TM, indicate that this animal developed an antigen-specific anamnes-
tic response to the BoHV-1 gD vaccine antigen.
Following dexamethasone induced immune suppression, an increase in anti-BoHV-4 titer
was observed in all four cattle used in this study. This result, in combination with sustained
VN anti-BVDV titers and the development of VN anti-BoHV-1 titers in all cattle without clini-
cal and molecular evidence of reactivated latent BoHV-1 infection, is consistent with persis-
tence of the recombinant virus and resultant recrudescence and boosting of the immune
response to the included immunogens. In this case, the magnitude of the VN anti-BVDV and
anti-BoHV-1 VN antibody responses is consistent with clinical protection from disease dic-
tated by the Code of Federal Regulations (9 CFR § 113.215 and 113.216, respectively) [25]. The
stability of the VN anti-BVDV titers in the face of dexamethasone suppression is consistent
with previous evidence that indicates that dexamethasone suppression does not reduce the VN
activity in cattle that have preexisting BVDV VN antibodies [41].
The precipitous increase in anti-BoHV-1 antibodies detectable by ELISA, and the develop-
ment of BoHV-1 neutralizing antibodies in all four cattle following dexamethasone suppres-
sion is interesting. One possibility considered to explain this logarithmic seroconversion is
that these animals were previously exposed to BoHV-1 and were in a state of clinical latency
without detectable evidence of BoHV-1 infection. Dexamethasone suppression is considered
the method of choice to reactivate latent alphaherpesviruses, specifically BoHV-1, and viremia
is consistently detectable by PCR from peripheral blood [42]. In our study, dexamethasone
suppression did not yield any evidence of BoHV-1 infection via VI and PCR testing of the
peripheral blood, nasal secretions, or postmortem tissue samples, thus making this an unlikely
scenario. Post-dexamethasone gD subunit studies are lacking in bovine vaccinology research,
however, antibody responses tend to increase in dexamethasone suppressed, latently BoHV-
1-infected animals [42]. Another possibility considered is that BoHV-4-A-CMV-IgK-
gE2gD-TM incited vector-neutralizing antibody responses. Although this possibility of inter-
nal neutralization could suggest impedance of the vector to elicit antibody responses, it also
suggests that potential in vivo recrudescence of live BoHV-1 was neutralized, based on the
inability to detect BoHV-1 infection, and would also indicate success of the vaccine. Regard-
less, an increase in the seropositivity post-dexamethasone suppression indicates a source of
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persistent antigen exposure. In the absence of any evidence of infection with natural BoHV-1,
the most likely antigen source is the recombinant BoHV-4-A-CMV-IgK-gE2gD-TM.
In previous studies, successful co-culture of infectious BoHV-4 from PBLs is sporadic dur-
ing the acute infection and undetectable in later stages of infection [29]. This was consistent
with our results following nebulization of WT BoHV-4. However, another previous study
described the detection of recrudescent BoHV-4 by culture of the peripheral blood following
dexamethasone suppression of cattle in the absence of detectable clinical signs [32]. Thus, VI
was attempted following dexamethasone-induced suppression. No infectious virus was
detected in circulation via co-culture of PBLs, nasal secretions, or in post-mortem tissue sam-
ples including the lung, liver, kidney, spleen, tracheobronchial lymph node, trigeminal nerve
ganglia, or bone marrow. It should be noted that in these previous studies, VI after dexametha-
sone administration from the peripheral blood required no less than 108 cells, and even then
detection via PCR evaluation is sporadic [32]. Additionally, dexamethasone administration
occurred within two months of the initial experimental infection in these studies, as opposed
to almost one year following BoHV-4-A-CMV-IgK-gE2gD-TM immunization and 1.5 years
after initial WT BoHV-4 infection in our studies. In our studies, approximately 103 PBLs were
collected and tested from each steer for each time point, thereby markedly decreasing the
chance of successful isolation. The effect of timing of dexamethasone administration in rela-
tion to initial infection has not been explored in regards to detectability of BoHV-4, but the
possibility that this detrimentally affected the ability to culture virus was considered in this
study. To the author’s knowledge, co-culture of BoHV-4 from post-mortem tissue samples has
not been described on dexamethasone treated cattle.
As previously stated, the decision to immunize via the intranasal route was made to most
accurately mimic the natural pathogenesis of gammaherpesviral infection, resulting in optimi-
zation of infection efficiency. Intranasal immunization has other fortuitous functional and
logistical advantages. First, intranasal delivery of an antigen has been shown to produce potent
systemic protective immunity, due at least in part to the fact that the upper respiratory mucosa
is rich in lymphoid tissue and functional antigen presenting dendritic cells [43]. Therefore, the
development of a protective immune response is expected and has been widely utilized in vet-
erinary vaccine development [44, 45]. Additionally, the noninvasive nature and ease of admin-
istration of intranasal vaccines facilitates widespread vaccine implementation [46, 47]. Lastly,
IN vaccines are needleless and therefore decrease the risk of iatrogenic blood-borne pathogen
transmission. These properties of intranasal vaccines tremendously increase the field-use
potential for use in livestock production management.
Our data supports the use of recombinant BoHV-4 as a vaccine vector for cattle. Most sig-
nificantly, these findings indicate that BoHV-4-vectored vaccines are able to elicit protective
immunity to included antigens following immunization of cattle; robust immune responses to
BoHV-4-vectored antigens are elicited following immunization with recombinant BoHV-4,
even in the face of pre-existing BoHV-4 immunity; recombinant BoHV-4 persists in cattle fol-
lowing immunization, and recrudescence of the virus boosts the immune response to BoHV-
4-vectored antigens; and the recombinant BoHV-4 vaccine can be delivered via the intranasal
route. These findings emphasize the substantial potential of recombinant BoHV-4-vectored
bovine vaccines, and provide rationale for further studies in BoHV-4 vectored vaccine
development.
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5. Egyed L, Ballagi-Pordány A, Bartha A, Belák S. Studies of in vivo distribution of bovine herpesvirus type
4 in the natural host. Journal of clinical microbiology. 1996; 34(5):1091–5. PMID: 8727882
6. Osorio FA. Experimental inoculation of cattle with bovine herpesvirus-4: evidence for a lymphoid-asso-
ciated persistent infection. 1983.
7. Morgan RW, Gelb J Jr., Schreurs CS, Lutticken D, Rosenberger JK, Sondermeijer PJ. Protection of
chickens from Newcastle and Marek’s diseases with a recombinant herpesvirus of turkeys vaccine
expressing the Newcastle disease virus fusion protein. Avian diseases. 1992; 36(4):858–70. PMID:
1485872
8. Tsukamoto K, Saito S, Saeki S, Sato T, Tanimura N, Isobe T, et al. Complete, long-lasting protection
against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus
vector expressing VP2 antigens. Journal of virology. 2002; 76(11):5637–45. https://doi.org/10.1128/
JVI.76.11.5637-5645.2002 PMID: 11991992
9. Li Y, Reddy K, Reid SM, Cox WJ, Brown IH, Britton P, et al. Recombinant herpesvirus of turkeys as a
vector-based vaccine against highly pathogenic H7N1 avian influenza and Marek’s disease. Vaccine.
2011; 29(46):8257–66. https://doi.org/10.1016/j.vaccine.2011.08.115 PMID: 21907750
Bovine herpesvirus-4 as a novel vaccine vector in cattle
PLOS ONE | https://doi.org/10.1371/journal.pone.0215605 April 19, 2019 14 / 16
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